Aer Therapeutics, Inc.
Aer Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel inhaled treatments for muco-obstructive lung diseases, focusing initially on COPD and expanding to other conditions like asthma, cystic fibrosis, and bronchiectasis. Their mission is to advance the treatment paradigm for mucus-mediated lung diseases through innovative therapies such as AER-01, a mucolytic designed to liquify mucus plugs in the lungs.
Industries
Nr. of Employees
small (1-50)
Aer Therapeutics, Inc.
Raleigh, North Carolina, United States, North America
Products
Inhaled thiol-modified carbohydrate mucolytic clinical candidate
A clinical-stage small-molecule mucolytic designed to cleave mucin disulfide bonds and liquefy airway mucus plugs, formulated for nebulizer and dry powder inhaler delivery.
Inhaled thiol-modified carbohydrate mucolytic clinical candidate
A clinical-stage small-molecule mucolytic designed to cleave mucin disulfide bonds and liquefy airway mucus plugs, formulated for nebulizer and dry powder inhaler delivery.
Services
Clinical development of inhaled respiratory therapeutics
Design and operational execution of early-phase clinical studies for inhaled mucolytic candidates, including patient selection using imaging biomarkers.
CMC and clinical supply management
Oversight of drug substance manufacturing, process and analytical development, and production of clinical trial API through external manufacturing partners.
Imaging biomarker development and quantitative lung analysis
Development and application of CT-based mucus plug scoring systems to identify patients with high mucus burden and to monitor therapeutic effects.
Clinical development of inhaled respiratory therapeutics
Design and operational execution of early-phase clinical studies for inhaled mucolytic candidates, including patient selection using imaging biomarkers.
CMC and clinical supply management
Oversight of drug substance manufacturing, process and analytical development, and production of clinical trial API through external manufacturing partners.
Imaging biomarker development and quantitative lung analysis
Development and application of CT-based mucus plug scoring systems to identify patients with high mucus burden and to monitor therapeutic effects.
Expertise Areas
- Inhaled drug development
- Mucolytic therapeutic development
- Preclinical translational research
- CT-based imaging biomarkers for lungs
Key Technologies
- Thiol-based disulfide bond reduction chemistry
- Inhalation delivery (nebulizer and dry powder)
- Quantitative CT lung imaging and scoring
- Preclinical translational models